Exhibit 99.1

Unaudited Condensed Interim Consolidated Financial Statements of

Concordia Healthcare Corp.

March 31, 2015

[1]

[2]

[3]

The accompanying notes are an integral part of these consolidated financial statements.

[4]

The accompanying notes are an integral part of these consolidated financial statements.

[5]

The accompanying notes are an integral part of these consolidated financial statements.

[6]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Concordia Healthcare Corp. (the “Company”, “Concordia” or the “Group”) is an integrated healthcare company that targets three areas: (a) legacy pharmaceutical products; (b) specialized healthcare distribution that services the growing diabetic market; and (c) the acquisition and/or development of orphan drugs.

These three business units are run as separate divisions but are inter-related. The cash-flow from legacy pharmaceutical products is used to fund operations and is also intended to fund the expansion of indications for potential orphan drugs. The specialized healthcare distribution division provides additional growth and cash-flow generation. Additionally, through its registered pharmacy operation, this business is intended to provide a specialty distribution capability for orphan drugs once acquired and/or developed. The three business units were acquired during 2013 and are expected to provide the Company with an increased market share of the related products, as well as savings in costs through economies of scale. During 2014, the Company has grown the Legacy Pharmaceuticals Division through the acquisition of Donnatal ^® and Zonegran ^® .

Concordia Healthcare Corp.’s shares were listed for trading on the TSX under the symbol “CXR” on December 24, 2013.

The registered and head office of the Company is located at 277 Lakeshore Rd. East, Suite 302, Oakville, Ontario, L6J 1H9.

[7]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

These condensed interim consolidated financial statements for the three months ended March 31, 2015 have been prepared in accordance with IAS 34, Interim Financial Reporting. These condensed interim consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with Concordia’s annual financial statements as at December 31, 2014.

Acquisitions during the year ended December 31, 2014 and three months ended March 31, 2015 have been accounted for as business combinations using the acquisition method. The consideration transferred in a business combination is measured at fair value at the date of acquisition. Acquisition-related transaction costs are recognized in income and comprehensive income as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognized at their fair value, except that:

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer’s previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer’s previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain.

[8]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

When the consideration transferred by the Group in a business combination includes assets or liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in the fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date.

The subsequent accounting for changes in the fair value of the contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is remeasured at subsequent reporting dates in accordance with IAS 39, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss.

The accounting policies adopted in the preparation of the condensed interim consolidated financial statements are consistent with those followed in the preparation of the Company’s annual consolidated financial statements for the year ended December 31, 2014, except as described below:

Restricted and Deferred Share Unit Plans

The expenses related to the Restricted Share Units (“RSUs”) and Deferred Share Units (“DSUs”) are accrued based on fair value, determined as of the date of grant. This expense is recognized as compensation expense over the vesting period. Until the liability is settled, the fair value of the RSUs and DSUs is remeasured at the end of each reporting period and at the date of settlement, with changes in fair value recognized as share-based compensation expense or recovery over the vesting period.

[9]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

The Donnatal Transaction

On May 15, 2014, Concordia, through its subsidiary, Concordia Pharmaceuticals Inc. (“CPI”), completed the purchase of Donnatal ^® , pursuant to the terms and conditions of a definitive agreement, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals. Donnatal ^® is an adjunctive therapy in the treatment of irritable bowel syndrome (“IBS”) and acute enterocolitis.

The purchase price paid to Revive Pharmaceuticals was $329,151 comprised of $200,000 in cash and an aggregate of 4,605,833 common shares of the Company valued at $129,151 based on the closing price of the Company’s stock on May 15, 2014 of CAD$30.50 per share converted to USD using the May 15, 2014 Bank of Canada closing USD: CAD exchange rate of 1:1.0877.

The Company paid for the cash component of the acquisition through a combination of available cash and debt financing. Accordingly, the Company entered into a secured credit facility having a principal amount of up to $195,000, consisting of a $170,000 term loan and a $25,000 operating line (the “Credit Facility”) (Note 11). The obligations of the Company under the Credit Facility are secured by the assets of the Company and the assets of its material subsidiaries. The Company expensed $8,314 of transaction costs in relation to the acquisition.

The purchase price has been allocated as follows:

The goodwill arising on acquisition is deductible for tax purposes.

[10]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

The Zonegran Transaction

On September 30, 2014, Concordia, through its subsidiary CPI, completed the purchase of Zonegran ^® for commercialization and sale in the United States, including Puerto Rico, from Eisai Inc. (“Eisai”), pursuant to the terms and conditions of a definitive agreement. Zonegran ^® is an adjunctive therapy in the treatment of partial seizures in adults with epilepsy.

The purchase price paid to Eisai was $91,402 in cash, which included approximately $1,402 for purchased inventory.

The Company paid for the acquisition through debt financing. Accordingly, the Company entered into an incremental senior credit facility of $95,000 (the “Incremental Term Loan”) (Note 14) by way of an amendment and restatement of the Credit Facility. All obligations of the Company under the Incremental Term Loan and the amended and restated Credit Facility are secured by the assets of the Company and the assets of its material subsidiaries. The Company expensed $3,849 of transaction costs in relation to the acquisition.

The purchase price has been allocated as follows:

There were $118 of write-offs recorded during the three months ended March 31, 2015 (2014 - $53).

[11]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Inventory amounts charged to cost of sales during the three months ended March 31, 2015 is $2,685 (2014 – $1,444). The Company increased its reserve for obsolete inventory by $7 during the quarter.

Prepaid expenses and other current assets, as at March 31, consist of the following:

[12]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

[13]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Acquired product rights include brands, trademarks and patents that were acquired as part of the transactions described in Note 3. In 2014 the Company reassessed the useful lives of its intangible assets and changed the estimate for certain acquired product rights from an indefinite life to useful lives ranging from 15 to 30 years.

The customer list was acquired as part of the acquisition of assets from Global Medical Direct LLC and affiliated entities (collectively “Global”). The transaction was completed on October 25, 2013 and had an effective date of August 1, 2013.

The intellectual property was acquired on December 20, 2013 as part of the acquisition of Pinnacle Biologics, Inc. and its subsidiaries.

[14]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

The carrying value of goodwill is reviewed at each reporting date to determine whether there exist any indications of impairment. As at March 31, 2015, there was no indication of impairment and no impairment loss has been recognized.

The following table describes movements in the Company’s provisions balance:

The closing balance relates to provisions made to estimate the liabilities arising from chargebacks, returns, rebates and other price adjustments. Although these estimates and provisions relate to revenue recognition transactions, namely the sales of products, the payments made for the underlying transactions are made directly to the claimants concerned and not to the original customer. Payments are expected within 12 months from the balance sheet date. Invoices received for such charges and estimates are shown in the Accounts Payable when received. The provision is for the uninvoiced portion of the charges and estimates.

Credit Facility

On May 14, 2014, the Company entered into the Credit Facility of $170,000 with GE Capital Canada Finance, Inc. and a syndicate of lenders. The obligations of the Company under the Credit Facility are secured by the assets of the Company and the assets of its material subsidiaries. The Credit Facility bears a variable interest rate and matures on May 14, 2019 with fixed repayments required over the term to maturity, as well as mandatory repayments based on excess cash flow generated by the Company as defined in the Credit Facility agreement, calculated annually.

On September 30, 2014, the Company amended the Credit Facility to facilitate the acquisition of Zonegran ^® . An Incremental Term Loan of $95,000 was added to the Credit Facility solely for the acquisition of Zonegran ^® and related expenses. This amended and restated Credit Facility matures on October 1, 2020. All obligations of the Company under the amended and restated Credit Facility are secured by assets of the Company and the assets of its material subsidiaries.

[15]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Credit Facility (continued)

Interest rates are calculated at the U.S. Prime Rate or LIBOR plus applicable margins based on a leverage table. The amended and restated Credit Facility contains standard events of default which if not remedied within a cure period would trigger the repayment of any outstanding balance. As at March 31, 2015, no such events of default have occurred.

Under the terms of the amended and restated Credit Facility, the Company is required to comply with certain financial covenants, as defined under the amended and restated Credit Facility, under which the Company’s total leverage ratio cannot exceed 4.25:1.00, the senior leverage ratio cannot exceed a certain cap ranging from 3.25:1.00 to 2.25:1.00, and the fixed charge ratio cannot be less than 1.11:1. Throughout the year ended December 31, 2014 and as at March 31, 2015, the Company was in compliance with all of the financial covenants. Transaction costs associated with the amended and restated Credit Facility have been included as a reduction to the carrying amount of the liability and are amortized through interest and accretion expense using the effective interest rate method.

On April 21, 2015 the Company completed the acquisition of 18 products, comprised of 12 branded products, 5 authorized generic contracts and a product distributed by a third party in Australia pursuant to the terms of a distribution agreement, from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, “Covis”) for $1.2 billion in cash (the “Covis Acquisition”). As part of the financing related to the Covis Acquisition the Company decided that it would retire the amended and restated Credit Facility. As a result of this planned early repayment of the amended and restated Credit Facility, during the quarter ended March 31, 2015, the Company recognized $5,815 in accretion interest using an effective interest rate of 12.915% for the original term loan and 13.690% for the Incremental Term Loans. Interest expense on the amended and restated Credit Facility was $2,456 for the three months ended March 31, 2015. On April 21, 2015, the Company retired the amended and restated Credit Facility, and paid the remaining balances in full. See Note 23, Subsequent events.

Revolving Credit Facility

On May 14, 2014, the Company entered into a senior secured revolving credit facility (the “Revolving Facility”) in the principal amount of $25,000 with GE Capital Canada Finance, Inc. and a syndicate of lenders. The Revolving Facility is for working capital requirements and is repayable on demand. Loans under the Revolving Facility are repayable without any prepayment penalties, and bear interest at U.S. Prime Rate or LIBOR plus applicable margins based on a leverage table. The Company has not borrowed against the Revolving Facility and there is no balance outstanding against this facility as at March 31, 2015.

[16]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Notes payable, as at March 31, consist of the following:

The notes payable of $4,625 as at March 31, 2015 represents the value of the notes issued by the Company related to the acquisition of assets from Global. The notes are unsecured, have a total face value of $7,000 and a coupon interest rate of 6%. The notes have been recorded at the present value of expected payments with a market representative interest rate of 12%. Interest expense and accretion expense amount to $158 and $5 respectively for the three months ended March 31, 2015 ($169 and $32 respectively for the three months ended March 31, 2014). The effective interest rate has been determined to be 12.38%. Principal repayments are due subject to the achievement of certain EBITDA thresholds over the 7 year term of the note. Based on the most recent forecast of EBITDA for Complete Medical Homecare Inc. (“CMH”), a subsidiary of the Company, the Company reduced the notes payable liability by $800 in the first quarter of 2015 and recorded an associated gain in the fair value of contingent consideration in the statement of income and comprehensive income.

[17]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

An estimate of the range of outcomes for the contingent purchase consideration is as follows:

The Company is authorized to issue an unlimited number of common shares.

On March 11, 2014 the Company announced the completion of a short-form prospectus offering, on a “bought deal” basis, of 5,750,000 common shares of Concordia, which included an exercise by the underwriters of an over-allotment option of 15% (the “Offering”). Aggregate gross proceeds of the Offering were CAD $67,563. Net proceeds to the Company, after the deduction of underwriters’ fees and transaction expenses of CAD $4,469, were CAD $63,094.

[18]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

The Offering was completed at a price per common share of CAD $11.75.

The Company recorded net proceeds of $56,999.

On May 15, 2014, the Company issued an aggregate of 4,605,833 common shares to PBM Pharmaceuticals Inc. (carrying on business as Revive Pharmaceuticals) for the purchase of Donnatal ^® , valued at $129,151 based on the closing price of the Company’s stock on the TSX on May 15, 2014 of CAD$30.50 per share converted to USD using the May 15, 2014 Bank of Canada closing USD: CAD exchange rate of 1:1.0877.

The Company’s board of directors approved a $0.30 per common share annualized ‘eligible’ dividend with $0.075 per common share being paid to shareholders on a quarterly basis.

The below table sets forth changes in issued and outstanding common shares and warrants for the period from January 1, 2014 to March 31, 2015.

[19]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Employee Stock Option Plan

The Company has an incentive stock option plan that permits it to grant options to acquire common shares to its directors, officers, employees, and others. The maximum number of common shares which may be reserved for issue under the stock option plan cannot exceed up to ten percent (10%) of the common shares of the Company, issued and outstanding from time to time, on a non-diluted basis (which maximum number is inclusive of any common shares reserved for issuance pursuant to the Company’s long-term incentive plan), as determined by the Board of Directors. The exercise price at which any option may be exercised to acquire a common share of the Company must be not less than the lesser of (i) the closing trading price of the common shares on the TSX on the date of grant and (ii) the volume-weighted average price of the common shares on the TSX for the five trading days immediately preceding the date of grant. As at March 31, 2015, the company had issued a total of 2,325,000 options to executive officers, employees and non-management members of the Board of Directors (December 31, 2014 – 2,275,000).

During the three months ended March 31, 2015, 50,000 employee stock options were issued, 12,500 options were exercised, and 7,500 options were cancelled, leaving a balance of 1,955,000 unexercised options outstanding as at March 31, 2015.

As at March 31, 2015, 380,383 stock options (December 31, 2014 – 422,883) were available for grant under the stock option plan.

The Black-Scholes model was used to compute option values. Key assumptions used to value each grant are set forth in the table below:

Exercise price for each of the stock options issued agreed to the market prices at the date of issue.

As historical volatility of the Company’s common shares is not available, expected volatility is based on the historical performance of the common shares of other corporations with similar operations.

All the options issued have different vesting terms ranging from immediate vesting to vesting over a period of 3 years. All options issued have a life of 10 years.

For the three months ended March 31, 2015, the total compensation charged against income with respect to all stock options granted was $897 (2014 – $756). An amount of $897 (2014 – $756) has been recognized in shareholders’ equity related to these options for the three months ended March 31, 2015.

[20]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Long-Term Incentive Plan

The Company has a Long-Term Incentive Plan (“LTIP”). Under the terms of the LTIP, the Board of Directors may grant units (“Units”), which may be either restricted share units (“Restricted Share Units” or “RSUs”) or deferred share units (“Deferred Share Units” or “DSUs”) to officers, directors, employees or consultants of the Company. Each Unit represents the right to receive one common share in accordance with the terms of the LTIP.

The maximum number of common shares of the Company which may be reserved and set aside for issue under the LTIP in respect of awards of DSUs to DSU Participants, and for payments in respect of awards of RSUs to RSU Participants, shall not exceed 10% of the common shares issued and outstanding from time to time on a non-diluted basis (for purposes of clarity, the maximum number of common shares reserved and set aside for issue under the LTIP shall be inclusive of any common shares reserved for issuance pursuant to any other security based compensation arrangement of the Company, including the stock option plan of the Company).

On each vesting date, the Company will decide, in its sole discretion, whether to make all payments in respect of vested RSUs to the RSU Participant or vested DSUs to the DSU participants in cash, common shares issued from treasury or a combination thereof based on the fair market value of the common shares as at such date.

During the three months ended March 31, 2015, the Company issued 1,000 RSUs to a director which vested within ten (10) business days of the date of issuance. The $56 payment in respect of the vested RSUs was settled in cash and recorded in general and administrative expense.

Mercari Options

In connection with the completion of Company’s qualifying transaction, the Company issued 25,998 options to the former directors of the Company (the “Mercari Options”). Each one of the Mercari Options is exchangeable for one common share of the Company at an exercise price of CAD $4.81 for a period of ten years. The Mercari Options were valued using a Black-Scholes option-pricing model at $63.

A pricing model with observable market based inputs was used to estimate the fair value of the Mercari Options. The variables used to compute the values were as follows: an expected life of two years; a risk free rate of 1.2%; a volatility rate of 100%; and an exercise price and market price of CAD $4.81. All of the Mercari Options were exercised in the first quarter of 2014.

Agent Options

In connection with the private placement (the “Private Placement”) completed by Concordia Healthcare Inc., a subsidiary of the Company, and the closing of the Company’s qualifying transaction in December 2013, the Company issued 220,800 options (the “Agent’s Options”) to the syndicate of agents that conducted the Private Placement. The Agent’s Options have been valued using a Black-Scholes option-pricing model at $422 and this amount has been offset against the net proceeds from the Private Placement.

The fair value of Agent’s Options cannot be measured reliably by the Company, thus the equity instrument has been measured based on the amount recognized for goods received or services rendered during the vesting period based on the number of options expected to vest. The Company measures the fair value of the Agent’s Options using the Black-Scholes option-pricing model.

Each Agent’s Option is exchangeable for one common share of the Company at an exercise price of CAD $6.25 for a period of two years. During the three months ended March 31, 2015, nil options were exercised. The outstanding balance of unexercised options outstanding is 77,280 as at March 31, 2015.

[21]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

Information with respect to stock option transactions for the three months ended March 31, 2015 and December 31, 2014 is as follows:

For the options exercised during the three months ended March 31, 2015, the weighted average market price on the date of exercise was $49.54.

As at March 31, 2015 outstanding stock options were as follows:

[22]

Concordia Healthcare Corp.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended March 31, 2015 and 2014

(Stated in thousands of U.S. Dollars, except per share amounts)

(Unaudited)

The Company had the following related party transactions during the three months ended March 31, 2015 and 2014: